Peptide vaccine trials for melanoma: preclinical background and clinical results
- 31 December 2003
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 13 (6), 431-438
- https://doi.org/10.1016/j.semcancer.2003.09.007
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanomaImmunological Reviews, 2002
- Peptide‐specific CD8+ T‐cell evolution in vivo: Response to peptide vaccination with Melan‐A/MART‐1International Journal of Cancer, 2002
- Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distributionMelanoma Research, 1998
- Cloning and Characterization of the Genes Encoding the Murine Homoloties of the Human Melanoma Antigens MARTI and gp100Journal of Immunotherapy, 1997
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Dose‐dependent T cell tolerance to an immunodominant self peptideEuropean Journal of Immunology, 1994
- Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 moleculesCell, 1993
- The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1993
- Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune responseCell, 1991
- Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic miceCell, 1991